Can OCT-A Detect Alzheimer’s Disease Before It Becomes Symptomatic?
A new study1, published in JAMA Ophthalmology and led by Gregory P. Van Stavern, MD of Washington University, revealed that OCT Angiography (OCT-A)2 may be effective in the early detection of Alzheimer’s disease in cognitively healthy patients that have not yet exhibited any signs of the disease.
The study examined patients with bio marker positive findings for pre-clinical Alzheimer’s disease to determine if they had any retinal microvascular alterations detectable by OCT-A. The results showed that the foveal avascular zone was increased and mean interfoveal thickness was decreased in the biomarker positive group. To download a copy of the full study, go to: https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2697402
To learn more about this and the many other potential uses of OCT-A technology, make sure to attend the 3rd Annual ISSOCT Meeting on Feb. 10-11th in Fort Myers, FL. An esteemed group of the world’s leading ophthalmologists will gather to discuss new clinical findings made possible with Swept Source OCT (SS-OCT) and OCT Angiography technology. Join the conversation and register today at: https://www.issoct.com
- Bliss, Elizabeth O’Bryhim, MD,
PhD; Apte, Rajendra S., MD, PhD; Kung, Nathan, MD; Coble, Dean PhD; VanStavern, Gregory P., MD. Association of Preclinical Alzheimer Disease with Optical CoherenceTomographicAngiography Findings. JAMA Ophthalmology. 2018;136(11):1242-1248.
- Topcon OCT-A technology is not cleared for sale in the U.S.